Riluzole attenuates the effects of chemoconvulsants acting on glutamatergic and GABAergic neurotransmission in the planarian Dugesia tigrina

Eur J Pharmacol. 2013 Oct 15;718(1-3):493-501. doi: 10.1016/j.ejphar.2013.07.009. Epub 2013 Jul 18.

Abstract

Planarians, the non-parasitic flatworms, display dose-dependent, distinct (C-like and corkscrew-like) hyperkinesias upon exposure to 0.001-10 mM aqueous solutions of glutamatergic agonists (L-glutamate and N-methyl-D-aspartate (NMDA)) and 0.001-5 mM concentrations of the glutamate decarboxylase (GAD) inhibitor (semicarbazide). In the planarian seizure-like activity (PSLA) experiments the three chemoconvulsants displayed the following order of potency (EC50): L-glutamate (0.6mM)>NMDA (1.4 mM)>semicarbazide (4.5mM). Planarian hyperkinesias behavior counting experiments also revealed that riluzole (0.001 to 1mM), an anti-convulsive agent, displayed no significant behavioral activity by itself, but attenuated hyperkinesias elicited by the three chemoconvulsants targeting either glutamatergic or GABAergic neurotransmission with the following order of potency (IC50): NMDA (44.7 µM)>semicarbazide (88.3 µM)>L-glutamate (160 µM). Further, (+)-MK-801, a specific NMDA antagonist, alleviated 3mM NMDA (47%) or 3mM L-glutamate (27%) induced planarian hyperkinesias. The results provide pharmacological evidence for the presence of glutamatergic receptor-like and semicarbazide sensitive functional GAD enzyme-like proteins in planaria in addition to demonstrating, for the first time, the anti-convulsive effects of riluzole in an invertebrate model. High performance liquid chromatography coupled with fluorescence detection (HPLC-F) analysis performed on planarian extracts post no drug treatment (control) or treatment with 3mM semicarbazide, combination of 3mM semicarbazide and 0.1 mM riluzole, or 0.1 mM riluzole revealed that 3 mM semicarbazide induced 35% decrease in the GABA levels and a combination of 3mM semicarbazide and 0.1 mM riluzole induced 42% decrease in glutamate levels with respect to the control group.

Keywords: 2,3-Naphthalene dicarboxaldehyde (PubChem CID:96400); Dizocilpine maleate (PubChem CID: 1207); L-Glutamate (PubChem CID: 33032); N-Methyl-D-aspartate (PubChem CID: 22880); Riluzole hydrochloride (PubChem CID: 6419992); Semicarbazide hydrochloride (PubChem CID:11236); γ-Aminobutyric acid (PubChem CID: 119).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Convulsants / pharmacology*
  • Dizocilpine Maleate / pharmacology
  • Excitatory Amino Acid Agonists / pharmacology*
  • Glutamic Acid / metabolism*
  • Glutamic Acid / pharmacology
  • Hyperkinesis / drug therapy
  • Hyperkinesis / metabolism
  • Hyperkinesis / pathology
  • N-Methylaspartate / pharmacology
  • Planarians*
  • Receptors, Glutamate / metabolism
  • Riluzole / pharmacology*
  • Semicarbazides / pharmacology
  • Synaptic Transmission / drug effects*
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • Convulsants
  • Excitatory Amino Acid Agonists
  • Receptors, Glutamate
  • Semicarbazides
  • carbamylhydrazine
  • Glutamic Acid
  • gamma-Aminobutyric Acid
  • N-Methylaspartate
  • Dizocilpine Maleate
  • Riluzole